| Authors: |
Jacobson CA; Dana-Farber Cancer Institute, Boston, Massachusetts., Westin JR; The University of Texas MD Anderson Cancer Center, Houston, Texas., Miklos DB; Stanford University, Stanford, California., Herrera AF; City of Hope National Medical Center, Duarte, California., Ritz J; Dana-Farber Cancer Institute, Boston, Massachusetts., Rodig S; Department of Pathology, Brigham and Women's Hospital and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Arihara Y; Dana-Farber Cancer Institute, Boston, Massachusetts., Cao S; Kite, a Gilead Company, Santa Monica, California., Sun J; Kite, a Gilead Company, Santa Monica, California., Mao D; Kite, a Gilead Company, Santa Monica, California., Adhikary S; Kite, a Gilead Company, Santa Monica, California., Neumann F; Kite, a Gilead Company, Santa Monica, California., Grechko N; Kite, a Gilead Company, Santa Monica, California., Locke FL; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. |
